Insider · CIK 0001546216

Goff Brian

Reports to the SEC for 5 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001546216

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Director, Chief Executive Officer	AAward	+39K sh	—	—	39,000
2026-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−39K sh	—	—	39,000
2026-06-09	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+13.3K sh	—	—	13,300
2026-06-09	NTLAIntellia Therapeutics, Inc.A Award	Director	AAward	+9,200 sh	—	—	32,609
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−6,596 sh	$34.71	−$229K	184,508
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−13.5K sh	—	—	40,500
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+13.5K sh	—	—	191,104
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−12.5K sh	$34.71	−$433K	177,604
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+25.5K sh	—	—	190,076
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−25.5K sh	—	—	0
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−5,918 sh	$28.96	−$171K	164,548
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−3,870 sh	$28.96	−$112K	147,733
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−13K sh	—	—	26,000
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−18K sh	—	—	18,000
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−8,267 sh	$28.96	−$239K	157,466
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−8,500 sh	—	—	0
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+8,500 sh	—	—	151,603
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+13K sh	—	—	170,466
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+18K sh	—	—	165,733
2026-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Director, Chief Executive Officer	AAward	+174K sh	—	—	174,000
2026-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Director, Chief Executive Officer	AAward	+48K sh	—	—	48,000
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+12.8K sh	—	—	149,333
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−12.8K sh	—	—	0
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+25.5K sh	—	—	149,056
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−25.5K sh	—	—	25,528
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−6,230 sh	$27.09	−$169K	143,103
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−12.5K sh	$27.09	−$338K	136,583
2025-08-08	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−22.7K sh	—	—	0
2025-08-08	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−11.1K sh	$36.67	−$406K	123,528
2025-08-08	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+22.7K sh	—	—	134,613
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−12.5K sh	$33.54	−$418K	105,401
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+12.8K sh	—	—	118,151
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−12.8K sh	—	—	12,750
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−25.5K sh	—	—	51,056
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−6,229 sh	$33.54	−$209K	111,922
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+25.5K sh	—	—	117,872
2025-06-11	NTLAIntellia Therapeutics, Inc.A Award	Director	AAward	+8,000 sh	—	—	23,409
2025-06-11	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+11.5K sh	—	—	11,450
2025-03-03	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−4,153 sh	$35.54	−$148K	83,139
2025-03-03	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−8,794 sh	$35.54	−$313K	92,345
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+8,500 sh	—	—	87,292
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+18K sh	—	—	101,139
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Director, Chief Executive Officer	AAward	+39K sh	—	—	39,000
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Director, Chief Executive Officer	AAward	+143K sh	—	—	142,500
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−8,500 sh	—	—	8,500
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−18K sh	—	—	36,000
2024-08-08	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−22.7K sh	—	—	22,691
2024-08-08	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Director, Chief Executive Officer	SSale	−11.1K sh	$42.75	−$474K	78,792
2024-08-08	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+22.7K sh	—	—	89,883
2024-06-13	NTLAIntellia Therapeutics, Inc. · Stock Option (right to buy)A Award	Director	AAward	+22.3K sh	—	—	22,297

Recent filings

Accepted (ET)
Jun 234
Goff Brian0001439222-26-000089
SEC(opens sec.gov)
Jun 104
Goff Brian0001193125-26-266236
SEC(opens sec.gov)
Apr 64
Goff Brian0001439222-26-000057
SEC(opens sec.gov)
Mar 34
Goff Brian0001439222-26-000044
SEC(opens sec.gov)

Companies

Address

C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET

CAMBRIDGE, MA, 02139